Kyowa Kirin China Pharmaceutical Co., Ltd. clinical trials

Formerly part of Kyowa Kirin Co., Ltd., Sep 14, 2024 · source ↗

The registry lists 4 studies whose lead sponsor is Kyowa Kirin China Pharmaceutical Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 9, 2026.

Before and after it left Kyowa Kirin Co., Ltd.

First submitted before Kyowa Kirin China Pharmaceutical Co., Ltd. left Kyowa Kirin Co., Ltd.: 4
First submitted after Kyowa Kirin China Pharmaceutical Co., Ltd. left Kyowa Kirin Co., Ltd.: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Completed: 4

Phase

Phase 4: 2
Phase 2: 1
Phase 1: 1
Phase 3: 1

Where

China: 4

Registry sponsor names on this page

Kyowa Kirin China Pharmaceutical Co., Ltd.4 studies

Something wrong with this grouping? Tell us on the Kyowa Kirin Co., Ltd. page.

Studies

Recruiting first, then most recently updated. Showing 4 of 4. All Kyowa Kirin Co., Ltd. studies →

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic TherapyCompletedNCT06285370Phase 4
Sponsor listed in the registry: Kyowa Kirin China Pharmaceutical Co., Ltd. · First submitted before Kyowa Kirin China Pharmaceutical Co., Ltd. left Kyowa Kirin Co., Ltd.
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)CompletedNCT02868060Phase 1/2
Sponsor listed in the registry: Kyowa Kirin China Pharmaceutical Co., Ltd. · First submitted before Kyowa Kirin China Pharmaceutical Co., Ltd. left Kyowa Kirin Co., Ltd.
Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPTCompletedNCT03123406Phase 4
Sponsor listed in the registry: Kyowa Kirin China Pharmaceutical Co., Ltd. · First submitted before Kyowa Kirin China Pharmaceutical Co., Ltd. left Kyowa Kirin Co., Ltd.
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)CompletedNCT02868099Phase 3
Sponsor listed in the registry: Kyowa Kirin China Pharmaceutical Co., Ltd. · First submitted before Kyowa Kirin China Pharmaceutical Co., Ltd. left Kyowa Kirin Co., Ltd.